MTOR and B-cell chronic lymphocytic leukemia: Specifically, two studies investigated the efficacy of idelalisib, a PI3K-δ isoform inhibitor, approved for chronic lymphocytic leukaemia (CLL) [22], and that of the dual, pan PI3K/mTOR inhibitor NVP-BEZ235 [36].